MICHAEL JAN BARTEL joined the Department of Medicine as a gastroenterologist at Fox Chase Cancer Center. Bartel earned his medical degree at Ruprecht-Karls-University Heidelberg in Germany. He completed his residency at Dartmouth-Hitchcock Medical Center in Lebanon, N.H. In 2012, he joined the Department of Gastroenterology and Hepatology at the Mayo Clinic in Jacksonville, Fla., as...
On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
